Table 2 Response rate across the different patient characteristics
Clinically relevant reduction of migraine days in all migraine types (≥50%) | |||
|---|---|---|---|
Variable | Yes (n = 73) | No (n = 18) | P-value |
Gender | 0.747 | ||
Female | 63 (80.8%) | 15 (19.2%) | |
Male | 10 (76.9%) | 3 (23.1%) | |
Range of age | 0.035 | ||
0–20 | 1 (50.0%) | 1 (50.0%) | |
21–30 | 8 (57.1%) | 6 (42.9%) | |
31–40 | 21 (77.8%) | 6 (22.2%) | |
41–65 | 43 (89.9%) | 5 (10.4%) | |
Ethnicity | 0.015 | ||
Middle East | 30 (66.7%) | 15 (33.3%) | |
Asian | 16 (94.1%) | 1 (5.9%) | |
Europe | 19 (95.0%) | 1 (5.0%) | |
Rest of the world | 8 (88.9%) | 1 (11.1%) | |
Type of migraine | 0.008 | ||
Medication overuse headache | 7 (50.0%) | 7 (50.0%) | |
Episodic migraine | 29 (87.9%) | 4 (12.1%) | |
Chronic migraine | 37 (84.1%) | 7 (15.9%) | |
Dose increase | 0.369 | ||
Yes | 10 (71.4%) | 4 (28.6%) | |
No | |||